| Income Statement | 2025-09-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Product revenue | 9,097,692 | 3,453,003 | ||
| Cost of product revenue | 3,956,286 | 2,373,336 | ||
| Product gross profit | 5,141,406 | 1,079,667 | ||
| Collaborations revenue | 3,000,000 | - | ||
| Selling, general and administrative | 7,384,517 | 7,901,695 | ||
| Research and development | 4,983,362 | 5,065,181 | ||
| Total operating expenses | 12,367,879 | 12,966,876 | ||
| Loss from operations | -4,226,473 | -11,887,209 | ||
| Fair value change in warrant liability | -784,670 | 327,092 | ||
| Financing costs | 334,063 | 228,988 | ||
| Other nonoperating income (expense) | - | 125,179 | ||
| Other income, net | 170,492 | - | ||
| Loss before income taxes | -3,605,374 | -12,318,110 | ||
| Net loss | -3,605,374 | -12,318,110 | ||
| Basic (in dollars per share) | -0.09 | -0.46 | ||
| Basic (in shares) | 40,152,873 | 26,762,392 | ||
| Diluted (in dollars per share) | -0.09 | -0.46 | ||
| Diluted (in shares) | 40,152,873 | 26,762,392 | ||
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)